Cetuximab plus FOLFOX 6 as first line therapy for metastatic colorectal cancer

被引：0
|
作者：
Scott, J
Dakhil, S
Cosgriff, T
Pink, C
Butler, B
Boccia, RV
机构：
[1] Canc Ctr Kansas, Wichita, KS USA
[2] Int Oncol Network, Wichita, KS USA
[3] Hematol & Oncol Specialists LLC, New Orleans, LA USA
[4] Canc Ctr Colorado Springs, Colorado Springs, CO USA
[5] Int Oncol Network Clin Res, Baltimore, MD USA
[6] Ctr Canc & Blood Disorders, Bethesda, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：297S / 297S
页数：1
相关论文
共 50 条
  • [41] Results of a Phase II Trial of Cetuximab plus Capecitabine/Irinotecan as First-Line Therapy for Patients with Advanced and/or Metastatic Colorectal Cancer
    Cartwright, Thomas
    Kuefler, Paul
    Cohn, Allen
    Hyman, William
    Berger, Maury
    Richards, Donald
    Vukelja, Svetislava
    Nugent, John E.
    Ruxer, Robert L., Jr.
    Boehm, Kristi A.
    Asmar, Lina
    CLINICAL COLORECTAL CANCER, 2008, 7 (06) : 390 - 397
  • [42] Cetuximab plus FOLFIRI as first-line treatment for metastatic colorectal CA.
    Rougier, P
    Raoul, JL
    Van Laethem, JL
    Peeters, M
    Husseini, F
    Brezault, C
    Cals, L
    Vedovato, JC
    Mueser, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 248S - 248S
  • [43] FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer
    Aparicio, Jorge
    Fernandez-Martos, Carlos
    Vicent, Jose M.
    Maestu, Inmaculada
    Llorca, Cristina
    Busquier, Isabel
    Campos, Jan M.
    Perez-Enguix, Daniel
    Balcells, Miquel
    CLINICAL COLORECTAL CANCER, 2005, 5 (04) : 263 - 267
  • [44] Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study
    Bendell, Johanna C.
    Tournigand, Christophe
    Swieboda-Sadlej, Anna
    Barone, Carlo
    Wainberg, Zev A.
    Kim, Jong Gwang
    Pericay, Carles
    Pastorelli, Davide
    Tarazi, Jamal
    Rosbrook, Brad
    Bloom, Joanna
    Ricart, Alejandro D.
    Kim, Sinil
    Sobrero, Alberto F.
    CLINICAL COLORECTAL CANCER, 2013, 12 (04) : 239 - 247
  • [45] Bevacizumab plus XELOX as first-line therapy for patients with metastatic colorectal cancer
    Gaspar, E.
    Juarez Marroqui, A.
    Vicent, J.
    Llorca, C.
    Orts, D.
    Galan, A.
    Barrajon, E.
    Cervera Grau, J.
    Giner, V.
    Macia, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] Impact of primary tumor side on clinical outcomes of first-line cetuximab plus FOLFOX-4 in RAS wild-type metastatic colorectal cancer
    Qin, Shukui
    Liu, Tianshu
    Xu, Jianming
    Li, Qi
    Cheng, Ying
    Zhang, Aimar
    Esser, Regina
    Chang, Helena
    Li, Jin
    FUTURE ONCOLOGY, 2023, 19 (15) : 1053 - 1061
  • [47] Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study
    Infante, Jeffrey R.
    Reid, Tony R.
    Cohn, Allen L.
    Edenfield, William J.
    Cescon, Terrence P.
    Hamm, John T.
    Malik, Imtiaz A.
    Rado, Thomas A.
    McGee, Philip J.
    Richards, Donald A.
    Tarazi, Jamal
    Rosbrook, Brad
    Kim, Sinil
    Cartwright, Thomas H.
    CANCER, 2013, 119 (14) : 2555 - 2563
  • [48] Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6+cetuximab (FX plus C) or FOLFIRI plus cetuximab (FF plus C): The CECOG/CORE1.2.001 trial
    Koza, I., Sr.
    Wrba, F.
    Vrbanec, D.
    Ocvirk, J.
    Ciuleanu, T. E.
    Beslija, S.
    Papamichael, D.
    Messinger, D.
    Zielinski, C. C.
    Brodowicz, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience
    Bokemeyer, C.
    Bondarenko, I.
    Hartmann, J. T.
    De Braud, F. G.
    Volovat, C.
    Nippgen, J.
    Stroh, C.
    Celik, I.
    Koralewski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] COST-EFFECTIVENESS OF BEVACIZUMAB VERSUS CETUXIMAB VERSUS PANITUMUMAB COMBINED WITH FIRST-LINE FOLFOX FOR METASTATIC COLORECTAL CANCER IN BRAZIL
    Sasse, Andre
    Carvalho, Adriana
    ANNALS OF ONCOLOGY, 2012, 23 : 100 - 100
12345